Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabazitaxel liposome
- Development stage
- Phase 1
- Lead developer
- Shandong New Era Pharmaceutical
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
XZ126 is a liposomal formulation of cabazitaxel, a semi-synthetic taxane derivative. Cabazitaxel works by binding to and stabilizing tubulin, which inhibits microtubule depolymerization and leads to cell cycle arrest in the G2/M phase, ultimately inducing apoptosis. The liposomal delivery system is designed to improve the pharmacokinetic profile, enhance tumor penetration, and potentially reduce the systemic toxicity associated with conventional cabazitaxel formulations (such as Jevtana). It is being developed by Shandong New Era Pharmaceutical and Shanghai Pharma for the treatment of previously treated solid tumors, including prostate cancer.
- Other names
- cabazitaxel liposome for injection
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cabazitaxel liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabazitaxel liposome.